Biomedical and healthcare equity fund Ares Life Sciences has taken a 40% stake in Italian ultrasound vendor Esaote.
Ares Life Sciences and previous majority shareholder Intesa Sanpaolo have agreed to create a new investor consortium to acquire 100% of the Milan, Italy-based firm's share capital for 280 million euros ($417.7 million U.S.). In addition to Intesa Sanpaolo and Ares Life Sciences, the new consortium will include other European investment firms and a group of managers led by current Esaote chairman and CEO Carlo Castellano.
In other Esaote news, the company will debut its MyLab One ultrasound scanner at this week's Medica conference in Düsseldorf, Germany. MyLab One includes an ultrasound scanner in a 12-inch touchscreen display, according to the firm.
The lightweight and portable system can be used in a variety of applications, including radiology, cardiology, orthopedics, anesthesia, and sports medicine, Esaote said. The company believes the scanner is also suitable for use during first-aid, emergency situations, vascular screening, and by general practices.
Related Reading
Esaote sales advance in 2008, March 31, 2009
Esaote develops ultrasound contrast concept, February 6, 2009
Biosound Esaote debuts new MyLab units, November 13, 2008
Biosound Esaote to license RCT harmonic patents, January 3, 2008
Biosound Esaote readies ACC introductions, March 20, 2007
Copyright © 2009 AuntMinnie.com
